Akin Gump today announced that Gorav Jindal has joined the firm as a partner in its antitrust practice in Washington. Mr. Jindal, who counsels clients on the antitrust aspects of mergers, acquisitions and joint ventures, comes to Akin Gump from Dechert.
Mr. Jindal’s practice combines government and private sector experience on behalf of clients in a variety of industries, including pharmaceutical, supermarket chain, specialty chemical, travel management and global distribution service, online recruiting, dairy and casino. For these clients, he handles all phases of merger investigations conducted by the U.S. Department of Justice and the Federal Trade Commission (FTC). He has steered clients through the antitrust aspects of transformative transactions and antitrust litigation and was a key member of the team that won Global Competition Review’s antitrust “Matter of the Year” award in 2014.
“Gorav represents the true Akin Gump spirit, combining an incredible knowledge of the law with intense client commitment, a highly collaborative approach to working with his colleagues and a commitment to giving back to his community,” said Akin Gump chairperson Kim Koopersmith. “He adds a significant dimension to our merger advice capabilities and will be a strong complement to our clients in the corporate, health care and intellectual property spaces. I am excited to have Gorav here at Akin Gump and welcome him to the firm.”
“With Gorav on our team, we will continue to build on our existing strengths in client counseling, litigation and investigations,” said Stephen M. Baldini, head of Akin Gump’s litigation practice. “He brings great depth as well as extensive experience in a number of industries, particularly the health care world, which will be of great value, and we are thrilled he decided to join us.”
Added Kerry E. Berchem, head of Akin Gump’s corporate practice, “Gorav brings considerable strength to our transactional antitrust capabilities, having worked on many high-profile mergers during the past 16 years of private practice. He will be a great addition to our team, and we are enthusiastic about introducing him to our clients.”
One area of particular focus for Mr. Jindal is pharmaceuticals, where he has represented both large and small companies under FTC investigation for allegedly fixing prices, improperly listing patents, entering into illegal patent settlements and allegedly engaging in business practices designed to unfairly lengthen the lifecycle of branded drugs under the Hatch-Waxman Act.
Mr. Jindal also represents clients in antitrust litigation and in investigations of matters involving suspected price-fixing, bid-rigging and exclusive dealing.
“Akin Gump stands out as a go-to firm for companies in need of cutting-edge legal advice,” said Mr. Jindal. “I see great synergies between the firm’s corporate, health care/life sciences and energy practices and my own areas of focus, making this a perfect match for me. I am excited about working alongside the talented attorneys here.”
Source: www.akingump.com
